Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care
|
|
NIDA Home > Publications > Research Monographs > |
Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care |
|
|
|
|
NIDA Research Monograph, Number 131 [Printed in 1993]
This monograph is not available by chapter. The Table of Contents (below) is shown to assist in locating information prior to downloading the monograph.
Table of Contents Preface-----iii The Impact of Prescription Drug Control Systems on Medical Practice and Patient Care: A Summary of the NIDA Technical Review-----1 Guiding Principles of International and Federal Laws Pertaining to Medical Use and Diversion of Controlled Substances-----18 Session: Medical Use, Therapeutic Rationale-Prescribing and Control Issues Therapeutic Use of Opioids: Prescribing and Control Issues-----35 Anxiolytics: Indications, Benefits, and Risks of Short, and Long-Term Benzodiazepine Therapy Current Research Data-----51 Issues and Controversies Regarding Benzodiazepine Use-----68 Stimulant Drugs-Medical Needs, Alternative Indications and Related Problems-----89 Session: Abuse and Diversion The Nonmedical Use of Prescription Drugs in the United States-----109 Drug Diversion Control Systems, Medical Practice, and Patient Care-----120 Session: Diversion Control Methods Existing Methods to Identify Retail Drug Diversion-----132 PADS Approach to Preventing Prescription Drug Diversion-----141 Diversion Investigation Units-Methods, Utilities, and Limitations-----145 OSTAR-Oklahoma Schedule Two Abuse Reduction: An Electronic Point of Sale Diversion Control System-----151 The Illinois Experience in Achieving the Medical/Regulatory Balance Required to Control Prescription Drug Diversion-----159 New York State's Triplicate Prescription Program-----176 Triplicate Prescriptions in Washington State-----194 The Medicaid Prescription Drug Initiative-----200 Summary and Conclusions of a Review of Prescription Drug Diversion Control Methods-----206 Session: Impact on Medical Practice and Patient Care Professional Association Responses An American Medical Association Perspective on Preventing Prescription Drug Diversion-----224 Prescription Drug Regulation: Implications for Nursing and Health Care Delivery-Response of the American Nurses' Association-----228 Perspective of the American Pharmaceutical Association-----235 C. Edwin Webb Perspective of the Empire State Medical Association of the National Medical Association-----239 Prescribing Practices and Drug Abuse-Perspective of the American Society of Addiction Medicine . . . . . . . . . . . . . . . . . . . 242 Anne Geller Response of the American Academy of Child and Adolescent Psychiatry-----246 Advocacy Groups Impact of Drug Regulation and Diversion Control System on Legitimate Narcolepsy Patients Response of American Narcolepsy Association-----249 State Cancer Pain Initiatives-----260 Benzodiazepine Dependence-A Treatment Program Perspective-----266 A Public Citizen Health Research Group Perspective on Federal Triplicate Prescription Requirements for Controlled Substance Prescription Drugs-----270 Session: Evaluation of the Impact on Medical Practice and Medical Care Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations-----279 Changes in Prescribing Patterns in Long-Term Care Facilities and Impact on Incidence of Adverse Events-----294 Future Research Directions A Research Agenda for Prescription Drug Diversion Control-----309 The Impact of Prescription Drug Control Systems on Medical Practice and Patient Care-A Summary of Research Recommendations-----325 Appendix List of May 30-June 1, 1991 Technical Review Participants-----331 List of October 3-4, 1991 Research Advisory Panel Participants-----334 |
|
|
NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment |
|
